2020/07/22 ALA -1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI) Post author:alarpharm Post published:13 . 8 . 2020 Post category:Media releases You Might Also Like 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021 2021/04/12 ALA-1000 Receive Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) (Application No. 2019102895). 21 . 4 . 2021 2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020 2021/11/09 Alar Announce Results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients 10 . 11 . 2021 2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 8 . 6 . 2021
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021
2021/04/12 ALA-1000 Receive Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) (Application No. 2019102895). 21 . 4 . 2021
2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020
2021/11/09 Alar Announce Results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients 10 . 11 . 2021
2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 8 . 6 . 2021
